fda approval of tirzepatide approves new weight-loss drug Zepbound (tirzepatide) Eli Lilly seeks FDA approval

Of these, IRS-1 and IRS-2 are the most extensively studied and are known to have overlapping but also distinct biological roles

Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear

Prescription products may not be appropriate for all individuals

Treatment frequency depends on individual goals but is typically weekly or bi-weekly